Citations

Clear

4847 citation(s) found for "Tu, Eric".

Long‐Term Outcome of IPAA in Patients Presenting with Fulminant Ulcerative Colitis: A Matched Cohort Study
Fasen, Geoffrey S., Pandian, T.K. , Pavey, Emily S., Dozois, Eric J. , Boostrom, Sarah Y., Fasen, Geoffrey

Mayo Clinic

World Journal of Surgery | June 11, 2015 | Volume: 39 | Issue: 10 | Pages: 2590-2594

10.1007/s00268-015-3114-5 | PMID 26067636 Get It

AbstractBackgroundStudies reveal that ileal pouch‐anal anastomosis (IPAA) has long‐term success. These reports, however, use well‐selected cohorts and exclude patients presenting with fulminant colitis (FC). Herein, we aimed to characterize long‐term functional outcomes in patients with fulminant ulcerative colitis (UC) undergoing IPAA.MethodsA prospective database identified patients who underwent IPAA between 1998 and 2008. Patients with FC and chronic UC were matched by age, gender, date of surgery, and follow‐up duration. Clinical and laboratory parameters, immunomodulator use at the time of surgery, and functional outcomes were compared.ResultsForty patients with FC and 73 patients with chronic UC were identified. Preoperative albumin, hemoglobin, leukocyte count, and steroid dose were significantly different for those with FC. Average survey follow‐up was 5.2 years for FC and 6.7 years for chronic UC patients. Functional outcomes were not significantly different. The 3‐year fistula‐free rate was 91.4 versus 98.6 % and the 3‐year stricture‐free rate was 79.3 versus 87.2 % for FC versus chronic UC patients, respectively.ConclusionPatients undergoing colectomy for FC secondary to UC have similar long‐term functional outcomes after IPAA despite significantly worse presentation. This study confirms that IPAA is an appropriate and durable treatment for patients with FC.
Randomized Phase III Trial of Paclitaxel Once Per Week Compared With Nanoparticle Albumin-Bound Nab-Paclitaxel Once Per Week or Ixabepilone With Bevacizumab As First-Line Chemotherapy for Locally Recurrent or Metastatic Breast Cancer: CALGB 40502/NCCTG N06
Barry, William T., Moreno‐Aspitia, Alvaro , Lyss, Alan P., Cirrincione, Constance, Leung, Eleanor H., Toppmeyer, Deborah , Perez, Edith A. , Hudis, Clifford A. , Leung, Eleanor, Mayer, Erica L. , Naughton, Michael, Carey, Lisa A. , Hudis, Clifford, Rugo, Hope S. , Naughton, Michael J. , Winer, Eric P.

Mayo Clinic

Journal of Clinical Oncology | June 10, 2015 | Volume: 33 | Issue: 21 | Pages: 2361-2369

10.1200/jco.2014.59.5298 | PMID 26056183 Get It

PurposeWe compared nab-paclitaxel or ixabepilone once per week to paclitaxel with bevacizumab as first-line therapy for patients with advanced breast cancer (BC) to evaluate progression-free survival (PFS) for nab-paclitaxel or ixabepilone versus paclitaxel.Patients and MethodsEligible patients were age ≥ 18 years with chemotherapy-naive advanced BC. Patients were randomly assigned to bevacizumab with paclitaxel 90 mg/m2(arm A), nab-paclitaxel 150 mg/m2(arm B), or ixabepilone 16 mg/m2(arm C), once per week for 3 of 4 weeks. Planned enrollment was 900 patients, which would give 88% power to detect a hazard ratio of 0.73.ResultsIn all, 799 patients were enrolled, and 783 received treatment (97% received bevacizumab). Arm C was closed for futility at the first interim analysis (n = 241), and arm A (n = 267) and arm B (n = 275) were closed for futility at the second interim analysis. Median PFS for paclitaxel was 11 months, ixabepilone was inferior to paclitaxel (PFS, 7.4 months; hazard ratio, 1.59; 95% CI, 1.31 to 1.93; P < .001), and nab-paclitaxel was not superior to paclitaxel (PFS, 9.3 months; hazard ratio, 1.20; 95% CI, 1.00 to 1.45; P = .054). Results were concordant with overall survival; time to treatment failure was significantly shorter in both experimental arms v paclitaxel. Hematologic and nonhematologic toxicity, including peripheral neuropathy, was increased with nab-paclitaxel, with more frequent and earlier dose reductions.ConclusionIn patients with chemotherapy-naive advanced BC, ixabepilone once per week was inferior to paclitaxel, and nab-paclitaxel was not superior with a trend toward inferiority. Toxicity was increased in the experimental arms, particularly for nab-paclitaxel. Paclitaxel once per week remains the preferred palliative chemotherapy in this setting.
Association Between Atrial Fibrillation Symptoms, Quality of Life, and Patient Outcomes
Simon, DaJuanicia N., Go, Alan S. , Spertus, John A. , Fonarow, Gregg C. , Kowey, Peter R. , Mahaffey, Kenneth W. , Thomas, Laine , Chang, Paul, Piccini, Jonathan P. , Freeman, James V. , Spertus, John, Thomas, Laine E, Gersh, Bernard J. , Hylek, Elaine M. , Peterson, Eric D. , Spertus, John A

Mayo Clinic

Circulation: Cardiovascular Quality and Outcomes | June 10, 2015 | Volume: 8 | Issue: 4 | Pages: 393-402

10.1161/circoutcomes.114.001303 | PMID 26058720 Get It

Background— Instruments to assess symptom burden and quality of life among patients with atrial fibrillation (AF) have not been well evaluated in community practice or associated with patient outcomes. Methods and Results— Using data from 10 087 AF patients in the Outcomes Registry for Better Informed Treatment of AF (ORBIT-AF), symptom severity was evaluated using the European Heart Rhythm Association (EHRA) classification system, and quality of life was assessed using the Atrial Fibrillation Effect on Quality-of-Life (AFEQT) questionnaire. The association between AF-related symptoms, quality of life, and outcomes was assessed using Cox regression. The majority of AF patients (61.8%) were symptomatic (EHRA >2) and 16.5% had severe or disabling symptoms (EHRA 3–4). EHRA symptom class was well correlated with the AFEQT score (Spearman correlation coefficient −0.39). Over 1.8 years of follow-up, AF symptoms were associated with a higher risk of hospitalization (adjusted hazard ratio for EHRA ≥2 versus EHRA 1 1.23, 95% confidence interval, 1.15–1.31) and a borderline higher risk of major bleeding. Lower quality of life was associated with a higher risk of hospitalization (adjusted hazard ratio for lowest quartile of AFEQT versus highest 1.49, 95% confidence interval, 1.2–1.84), but not other major adverse events, including death. Conclusions— In a community-based study, most patients with AF were symptomatic and had impaired quality of life. Quality of life measured by the AFEQT correlated closely with symptom severity measured by the EHRA class. AF symptoms and lower quality of life were associated with higher risk of hospitalization but not mortality during follow-up.
A Large Multiethnic Genome-Wide Association Study of Prostate Cancer Identifies Novel Risk Variants and Substantial Ethnic Differences
Hoffmann, Thomas J. , Jorgenson, Eric , Habel, Laurel A. , Passarelli, Michael N. , Cario, Clinton L. , Emami, Nima C. , Chao, Chun , Ghai, Nirupa R. , Shan, Jun , Ranatunga, Dilrini K., Aaronson, David S., Presti, Joseph C. , Berndt, Sonja I. , McDonnell, Shannon K. , French, Amy J. , Schaid, Daniel J. , Thibodeau, Stephen N. , Freedman, Matthew L. , Mucci, Lorelei A. , Haiman, Christopher A. , Henderson, Brian E., Seminara, Daniela, Kvale, Mark , Schaefer, Catherine , Risch, Neil , Witte, John S. , Wang, Zhaoming , Van Den Eeden, Stephen K , Sakoda, Lori C. , Graff, Rebecca E. , Quesenberry, Charles P. , Wang, Zhaoming , Chanock, Stephen Jacob , Li, Qiyuan , Penney, Kathryn , Kwok, Pui–Yan , Wang, Zhaoming , McDonnell, Shannon K

Mayo Clinic

Cancer Discovery | June 2, 2015 | Volume: 5 | Issue: 8 | Pages: 878-891

10.1158/2159-8290.cd-15-0315 | PMID 26034056 Get It

Abstract A genome-wide association study (GWAS) of prostate cancer in Kaiser Permanente health plan members (7,783 cases, 38,595 controls; 80.3% non-Hispanic white, 4.9% African-American, 7.0% East Asian, and 7.8% Latino) revealed a new independent risk indel rs4646284 at the previously identified locus 6q25.3 that replicated in PEGASUS (N = 7,539) and the Multiethnic Cohort (N = 4,679) with an overall P = 1.0 × 10−19 (OR, 1.18). Across the 6q25.3 locus, rs4646284 exhibited the strongest association with expression of SLC22A1 (P = 1.3 × 10−23) and SLC22A3 (P = 3.2 × 10−52). At the known 19q13.33 locus, rs2659124 (P = 1.3 × 10−13; OR, 1.18) nominally replicated in PEGASUS. A risk score of 105 known risk SNPs was strongly associated with prostate cancer (P &lt; 1.0 × 10−8). Comparing the highest to lowest risk score deciles, the OR was 6.22 for non-Hispanic whites, 5.82 for Latinos, 3.77 for African-Americans, and 3.38 for East Asians. In non-Hispanic whites, the 105 risk SNPs explained approximately 7.6% of disease heritability. The entire GWAS array explained approximately 33.4% of heritability, with a 4.3-fold enrichment within DNaseI hypersensitivity sites (P = 0.004). Significance: Taken together, our findings of independent risk variants, ethnic variation in existing SNP replication, and remaining unexplained heritability have important implications for further clarifying the genetic risk of prostate cancer. Our findings also suggest that there may be much promise in evaluating understudied variation, such as indels and ethnically diverse populations. Cancer Discov; 5(8); 878–91. ©2015 AACR. This article is highlighted in the In This Issue feature, p. 783
Recent advances in 3D time-resolved contrast-enhanced MR angiography
Riederer, Stephen J. , Haider, Clifton R. , Borisch, Eric A. , Weavers, Paul T., Young, Phillip M.

Mayo Clinic

Journal of Magnetic Resonance Imaging | June 2, 2015 | Volume: 42 | Issue: 1 | Pages: 3-22

10.1002/jmri.24880 | PMID 26032598 Get It

Molecular Phenotype of Breast Cancer According to Time Since Last Pregnancy in a Large Cohort of Young Women
Collins, Laura C. , Gelber, Shari , Marotti, Jonathan D. , Ruddy, Kathryn J. , Brachtel, Elena F. , Schapira, Lidia , Come, Steven E. , Wensley, Taylor, White, Sarah, Borges, Virginia F. , Schedin, Pepper , Tamimi, Rulla M. , White, Sarah Ann , Warner, Ellen , Winer, Eric P. , Partridge, Ann H.

Mayo Clinic

The Oncologist | May 30, 2015 | Volume: 20 | Issue: 7 | Pages: 713-718

10.1634/theoncologist.2014-0412 | PMID 26025931 Get It

Abstract Background. The increase in breast cancer risk during pregnancy and postpartum is well known; however, the molecular phenotype of breast cancers occurring shortly after pregnancy has not been well studied. Given this, we investigated whether nulliparity and the time interval since pregnancy among parous women affects the breast cancer phenotype in young women. Materials and Methods. We examined molecular phenotype in relation to time since pregnancy in a prospective cohort of 707 young women (aged ≤40 years) with breast cancer. Parity was ascertained from study questionnaires. Using tumor histologic grade on central review and biomarker expression, cancers were categorized as luminal A- or B-like, HER2 enriched, and triple negative. Results. Overall, 32% were luminal A-like, 41% were luminal B-like, 9% were HER2 enriched, and 18% were triple negative. Although, numerically, patients diagnosed &gt;5 years after pregnancy had more luminal A-like subtypes than women with shorter intervals since pregnancy, there was no evidence of a relationship between these intervals and molecular subtypes once family history of breast cancer and age at diagnosis were considered. Conclusion. Distribution of breast cancer molecular phenotype did not differ significantly among young women by parity or time interval since parturition when important predictors of tumor phenotype such as age and family history were considered. Implications for Practice: Distribution of breast cancer molecular phenotype did not differ among parous young women by time interval since pregnancy. The implication of these findings for clinical practice suggests that pregnancy-associated breast cancers may be seen up to 5 years beyond parturition.
Clinical Characteristics and Outcomes of Patients with and without Diabetes in the Surgical Treatment for Ischemic Heart Failure (STICH) Trial
MacDonald, Michael R. , She, Lilin , Doenst, Torsten , Binkley, Philip F. , Rouleau, Jean L. , Tan, Ru‐San , Lee, Kerry L., Miller, Alan B. , Szalewska, Dominika , Waclawiw, Myron A., Castelvecchio, Serenella , Adlbrecht, Christopher , Michler, Robert E. , Oh, Jae K. , Petrie, Mark C. , Sopko, George S. , Dąbrowski, Rafał , Velazquez, Eric J. , Petrie, Mark C

Mayo Clinic

European Journal of Heart Failure | May 26, 2015 | Volume: 17 | Issue: 7 | Pages: 725-734

10.1002/ejhf.288 | PMID 26011509 Get It

Abstract Aims Hypothesis 1 of the Surgical Treatment for Ischemic Heart Failure (STICH) trial enrolled 1212 patients with an LVEF of ≤35% and CAD amenable to coronary artery bypass grafting (CABG). Patients were randomized to CABG and optimal medical therapy (MED) or MED alone. The objective was to assess whether or not patients with diabetes mellitus (DM) enrolled in the STICH trial would have greater benefit from CABG than patients without DM. Methods and results The characteristics and clinical outcomes of patients with and without DM randomized to CABG and MED or MED alone were compared. DM was present in 40%. At baseline, patients with DM had more triple vessel CAD, higher LVEF, and smaller left ventricular volumes. In patients with DM, the primary outcome of all-cause mortality occurred in 39% of patients in the MED group and 39% in the CABG group [hazard ratio (HR) with CABG 0.96, 95% confidence interval (CI) 0.73–1.26]. In patients without DM, the primary outcome occurred in 41% of patients in the MED group and 32% in the CABG group (HR with CABG 0.80, 95% CI 0.63–1.02). While numerically it would appear that the treatment effect of CABG is blunted in patients with DM, there was no significant interaction between DM and treatment group on formal statistical testing. Conclusions Patients with DM enrolled in the STICH trial had more triple vessel disease, smaller hearts, and higher LVEF than those without DM. CABG did not exert greater benefit in patients with DM.